NR4A1 and chronic obstructive pulmonary disease: In conclusion, by showing that CS reduces Nur77 expression and activity and that a Nur77-specific agonist can reverse such Nur77 downregulation and counter exaggerated inflammatory responses in the lungs of mice and human airway epithelial cells, our study demonstrates potential therapeutic benefits of Nur77 activation for the treatment of COPD.